Latest news with #PDPS
Yahoo
5 days ago
- Business
- Yahoo
FDA Approved Anticancer Peptide Drug Conjugate Market Clinical Trials Insight
Global Peptide Drug Conjugate Market USD 1400 Million Opportunity Says Kuick Research In New Study Delhi, June 05, 2025 (GLOBE NEWSWIRE) -- Global Peptide Drug Conjugate Market, Drug Sales, Price, Dosage and Clinical Trials Insight 2030 Report Highlights: Global Peptide Drug Conjugate Market Opportunity: > USD 1400 Million Global Peptide Drug Conjugate Market Trends By Region and Indications Global Peptide Drug Conjugate Market Growth 2018-2024: > 300% Absolute Growth and 27% CAGR Growth Approved Peptide Drug Conjugate Dosage, Sales and Price Insight Approved Peptide Drug Conjugate Sales Global and Regional Insight: 2 Drugs Approved Global Peptide Drug Conjugate Clinical Trials Insight: > 30 Drugs Global Peptide Drug Conjugates Clinical Trials Insight By Company, Country, Indication and Phase Peptide Drug Conjugate Proprietary Technologies and Methodologies Insight By Company Download Report: Peptide drug conjugates constitute a novel category of targeted therapies that make use of disease-targeting peptides to specifically deliver small molecule drugs to the target cells. This blended strategy enables drugs to be targeted more precisely to ailing tissues, minimizing systemic toxicity and maximizing therapeutic benefit. With more than 30 peptide drug conjugates candidates now in different stages of clinical trials, the domain is accelerating at breakneck speed. Most of these candidates are being developed and evaluated for oncology, where the demand for highly targeted therapies is still paramount. Nonetheless, investigations have also been pushed into neurodegenerative disease and inflammatory disorders, which suggests a wider therapeutic scope for this modality. As of May 2025, 2 peptide drug conjugates have been approved by the regulators. Novartis's Lutathera, a radiolabeled peptide for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs), exemplifies the potential of targeted delivery in cancer. The second agent that has been approved, Pepaxti (melflufen), by Oncopeptides, is employed to treat multiple myeloma and demonstrates the utility of peptide to enhance the therapeutic index of known cytotoxic agents. All these achievements underscore the potential for peptide drug conjugates and have opened up doors for more firms to enter the pipeline for developing new candidates. Platform technologies are leading the way in driving peptide drug conjugate innovation. For example, PeptiDream's PDPS (Peptide Discovery Platform System) leverages massive libraries of macrocyclic peptides to quickly find high-affinity binders. They are optimized as targeting agents in peptide drug conjugates, enabling more targeted drug delivery. By targeting cytotoxic payloads directly to disease-associated receptors, these technologies reduce off-target effects, improving efficacy and safety for patients. The growing use of such platforms by biotech companies and pharmaceutical companies highlights their significance in the present drug development scenario. Regulatory assistance is also supporting the development of peptide drug conjugates. Sudocetaxel zendusortide (TH1902), a peptide drug conjugate from Theratechnologies, was granted the Fast Track Designation by the FDA. This candidate has been designed against sortilin-expressing solid tumors and is undergoing Phase 1 clinical trials. As the first compound from Theratechnologies' SORT1+ Technology™, it is an example of innovation in peptide targeting and an accelerated regulatory pathway that allows for accelerated development. Designations such as these not only support the therapeutic potential of these compounds but also foster investment and accelerate clinical advancement. The peptide drug conjugate field involves a diverse range of stakeholders, including major pharmaceutical companies like Novartis and Oncopeptides, as well as specialized biotechnology firms such as Bicycle Therapeutics and Theratechnologies. Additionally, contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs) are increasingly becoming integral to the development process, providing essential services from early-stage discovery through to clinical and commercial manufacturing. In spite of this momentum, market hurdles exist. One major hindrance is the complexity of peptide drug conjugate manufacturing, which sometimes necessitates specialized facilities and intense quality control, potentially pushing up development expense. To overcome it, strategic alliances with seasoned CDMOs can streamline manufacturing and lower operational costs. Regulatory complexity regarding newer payloads or novel peptide-linker chemistries is another hurdle. Anticipation of the regulatory agencies through proactive interaction and utilization of existing designations can smooth over the complexity. Looking to the future, the prospects for peptide-drug conjugates are encouraging. As ever improving technology platforms advance and additional clinical information becomes available, peptide drug conjugates are destined to become a staple of targeted therapy, not just oncology, but perhaps a wide variety of chronic and orphan diseases. CONTACT: Neeraj Chawla Research Head Kuick Research neeraj@ +91-470679900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Time of India
08-05-2025
- Business
- Time of India
PDPS to cover chilli farmers' losses in T
Hyderabad: The implementation of the ( ) under the Centre's (MIS) is expected to provide significant relief to chilli farmers in Telangana. The central agriculture department has clarified that farmers selling produce below the cost of cultivation will receive compensation to at least cover their production expenses. Tired of too many ads? go ad free now Accordingly, the department has directed the Telangana agriculture department to implement the scheme as per MIS month, Union coal minister G Kishan Reddy wrote to Union agriculture minister Shivraj Singh Chauhan, urging intervention to prevent losses for chilli farmers in Telangana. He pointed out that growers in districts such as Khammam, Mahabubabad, Jogulamba Gadwal, Bhadradri Kothagudem, Jayashankar Bhupalpally, Mulugu, Suryapet, Warangal, Hanumakonda, and Nagarkurnool were suffering due to market prices falling below production response, the central department announced that for the fiscal year 2024–25, the PDPS will cover 1,72,135 metric tonnes of chilli (25% of the state's estimated 6,88,540 metric tonnes).
Yahoo
19-03-2025
- Yahoo
Police: 1 injured, likely by his own knife, during Portage chase
PORTAGE, Mich. (WOOD) — A person was injured during a foot chase with police in Portage that involved a knife, a taser and a K-9, police say. Around 8:45 p.m., officers with the Portage Department of Public Safety tried to arrest a person who had felony warrants on Apple Street between Newells Lane and Oakside Street, according to PDPS Director Nick Armold. He ran off. Officers followed the person, who showed he had a knife at some point during the chase. Michigan State Police officers assisted Portage police. The person was eventually tased and stopped by a K-9, Armold said. The person was injured during the scuffle; Armold believes he may have fallen on his knife. He was treated at the scene and then taken to the hospital. The person was not identified. It's not clear what felony warrants he was wanted for. Armold said more information would be released Wednesday. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
CBS News
27-02-2025
- Automotive
- CBS News
New Jersey man mistakenly labeled 'problem driver,' blocked from renewing license
Joe Bruno has always considered himself a good driver, so he was shocked to receive a letter informing him he was ineligible to renew his license. "I try to follow the speed limits all the time," Bruno said. "You have to be careful." The letter from the New Jersey Motor Vehicle Commission stated he was flagged in a database of drivers whose privileges have been suspended or revoked. Even more puzzling, the letter said it was the state of New York that flagged him. But Bruno has never lived or driven in New York. "I don't drive in New York, I don't have a license in New York," he said. "I don't know what they're talking about." After weeks of unsuccessful attempts with both states to rectify the issue, and with time running out before his license was set to expire, Bruno emailed InYourCorner@ for help. Pinpointing the problem The letter Bruno received said his name matched a record in what's known as the Problem Driver Pointer System (PDPS). It's a federal database used by states to check for issues with someone's driving record before issuing a license. The system is designed to ensure someone whose driving privileges have been revoked or suspended in one state cannot receive or renew their license in another state. But CBS News Philadelphia found you can mistakenly land on the list simply for having a name similar to an actual "problem driver." "Bruno is a very common name, and Joseph Bruno is probably one of the most common Bruno names," said his wife Terry Bruno. Once someone is flagged as a "problem driver," the Brunos learned it can be difficult to fix the error. "He was broken, his license means everything to him, it's his independence," Terry Bruno said. "So for him to have to go through all this just because somebody else has the same name." Correcting the error Joe Bruno was told by the New Jersey Motor Vehicle Commission it was his responsibility to contact New York, the state that reported him to the "problem driver" system. Workers with the New York Department of Motor Vehicles told Bruno to fax documents including his birth certificate and social security card. They would review the information, he was told, and send what's called a "no match letter" for Bruno to take back to New Jersey proving he wasn't the "problem driver" in New York. But six weeks later, they were still waiting. That's when the Brunos contacted CBS News Philadelphia. "I said, 'I can't understand it, I'm really frustrated, my blood pressure is up, I'm in a bad mood, I can't sleep,'" Bruno said. "Then I look at Channel 3 and I see Josh on there helping people and I said, 'This is the last resort.'" CBS News Philadelphia cut through the red tape, clearing the way for Bruno to get his renewed license. The National Highway Traffic Safety Administration (NHTSA), the federal agency that operates the "problem driver" system, said it doesn't verify what's entered into the database. In an emailed statement, the agency said it's up to states to enter correct information. A spokesperson for NHTSA said the agency doesn't track how U.S. drivers each year are impacted by errors like this. We asked representatives with both the New Jersey Motor Vehicle Commission and New York Department of Motor Vehicles why they couldn't differentiate between different Joe Brunos. Neither would offer an explanation and each referred us to the other. Finally relieved to have his situation sorted out, Bruno said it shouldn't fall on the driver to fix false alerts when the mistake was made by the state. "I would have never gotten this far without you, Josh, I believe you really helped me," he said. If someone is unable to receive a response from a state licensing agency, NHTSA said they can contact the National Driver Register office at (202) 366-4800 to help facilitate a response from that state. You can find more information here on how to contact NHTSA if you're labeled a 'problem driver' in error.
Yahoo
04-02-2025
- Business
- Yahoo
Global Peptide-Drug Conjugate Market to Show Enormous Growth at a CAGR of ~29% by 2032
The increasing global prevalence of cancer is fueling the demand for peptide-drug conjugates as targeted therapies, providing improved effectiveness and lower systemic toxicity than conventional treatments. Additionally, the expanding use of peptide-based therapeutics, driven by their enhanced treatment outcomes, biocompatibility, and precise tumor-targeting capabilities, is further propelling market growth. LAS VEGAS , Feb. 4, 2025 /PRNewswire/ -- DelveInsight's Peptide-drug Conjugate Market Insights report provides the current and forecast market analysis, individual leading peptide-drug conjugate companies' market shares, challenges, peptide-drug conjugate market drivers, barriers, trends, and key market peptide-drug conjugate companies in the market. Key Takeaways from the Peptide-drug Conjugate Market Report As per DelveInsight estimates, North America is anticipated to dominate the global peptide-drug conjugate market during the forecast period. The LUTATHERA (lutetium Lu 177 dotatate) category in the peptide drug conjugates market dominated with a market share of 37% in 2024. Notable peptide-drug conjugate companies such as Novartis AG, Oncopeptides AB, Cybrexa Therapeutics, Avacta Therapeutics, ProteinQure, Theratechnologies Inc., CBP, Soricimed Biopharma, NMS Group S.p.A., Mainline Scientific LLC., Bicycle Therapeutics, and several others, are currently operating in the peptide-drug conjugate market. In April 2024, PeptiDream Inc. announced the expansion of its peptide discovery collaboration with Novartis Pharma AG. Using its proprietary Peptide Discovery Platform System (PDPS®), PeptiDream identified and optimized macrocyclic peptides for conjugation with radionuclides for therapeutic and diagnostic applications. In March 2023, Ono Pharmaceutical Co., Ltd. announced that it entered into a drug discovery collaboration agreement with PeptiDream Inc., to discover and develop novel macrocyclic constrained peptide drugs against multiple targets of Ono's interest. To read more about the latest highlights related to the PDC market, get a snapshot of the key highlights entailed in the Global Peptide-drug Conjugate Market Report Peptide-drug Conjugate Overview Peptide-drug conjugates (PDCs) are an emerging class of targeted therapeutics that combine the specificity of peptides with the potent efficacy of cytotoxic drugs. These conjugates leverage peptides as targeting ligands to deliver drugs selectively to diseased cells, such as cancerous or infected tissues, thereby minimizing off-target toxicity. The design of PDCs involves three key components: a targeting peptide, a linker, and a payload (therapeutic drug). The peptide is typically selected based on its ability to recognize and bind to overexpressed receptors on diseased cells, ensuring precise drug delivery. The linker plays a crucial role in controlling drug release, which can be triggered by specific conditions like enzymatic cleavage or pH changes in the tumor microenvironment. Compared to antibody-drug conjugates (ADCs), PDCs offer advantages such as smaller size, better tissue penetration, and lower immunogenicity. They are particularly promising for targeting intracellular pathways, where antibodies may struggle to enter. Advances in peptide engineering, including modifications to enhance stability and binding affinity, have further improved the efficacy of PDCs in preclinical and clinical settings. PDCs are being explored in various therapeutic areas, including oncology, infectious diseases, and metabolic disorders. As research progresses, optimizing peptide selection, linker chemistry, and payload potency will be critical in developing next-generation PDCs with superior safety and efficacy profiles. Peptide-drug Conjugate Market Insights North America dominated the global peptide drug conjugates market in 2024, accounting for the largest share of 56.70%. The market is expected to grow at a CAGR of 28.47% from 2025 to 2032, primarily driven by the increasing incidence of cancer in the U.S. Additionally, the region's market growth is fueled by rising collaborations among key industry players for PDC development and increasing investments in this sector. Furthermore, major companies in North America are emphasizing research and development to create innovative peptide-drug conjugates. For instance, in February 2021, Theratechnologies Inc. announced that the U.S. FDA granted fast-track designation to TH1902, a docetaxel-based peptide-drug conjugate, for treating patients with sortilin-positive recurrent advanced solid tumors that are resistant to standard therapies. In addition, in April 2024, Novartis, which already has two FDA-approved PDC drugs, expanded its collaboration with PeptiDream to further develop peptide-drug conjugates in a deal exceeding USD 2.8 billion. These factors collectively contribute to the anticipated growth of the peptide drug conjugates market in the region. To know more about why North America is leading the market growth in the PDC market, get a snapshot of the Peptide-drug Conjugate Market Outlook Peptide-drug Conjugate Market Dynamics The peptide-drug conjugate market is witnessing significant growth, driven by advancements in targeted therapies and the increasing prevalence of cancer and other chronic diseases. PDCs combine the specificity of peptides with the potency of cytotoxic drugs, offering an improved therapeutic index compared to traditional chemotherapy. With growing interest in precision medicine, pharmaceutical companies are heavily investing in PDC research and development, leading to an expanding pipeline of clinical candidates. One of the key market drivers is the rising demand for novel drug delivery systems that enhance efficacy while minimizing off-target effects. Peptides, due to their high specificity and low immunogenicity, serve as excellent carriers for cytotoxic payloads. Additionally, advancements in peptide synthesis and linker technologies have improved the stability and half-life of PDCs, making them more viable for clinical applications. Companies such as Bicycle Therapeutics and PeptiDream are leading the innovation in this space. Despite the promising outlook, the PDC market faces challenges such as manufacturing complexities, high development costs, and regulatory hurdles. Peptide synthesis and conjugation processes require stringent quality control, and scalability remains a concern. Furthermore, competition from other targeted therapies, such as ADCs and small-molecule inhibitors, poses a challenge for widespread adoption. Looking ahead, growth opportunities exist in expanding indications beyond oncology, such as antimicrobial, autoimmune, and neurodegenerative diseases. Strategic collaborations between biotech firms and large pharmaceutical companies are accelerating clinical development, while advancements in artificial intelligence and computational modeling are further refining peptide design and optimization. With ongoing innovations and increasing investments, the PDC market is poised for substantial expansion in the coming years. Get a sneak peek at the PDC market dynamics @ Peptide-drug Conjugate Market Dynamics Analysis Report Metrics Details Coverage Global Study Period 2022–2032 Peptide-drug Conjugate Market CAGR ~29% Peptide-drug Conjugate Market Size by 2030 ~USD 14 Billion Key Peptide-drug Conjugate Companies Novartis AG, Oncopeptides AB, Cybrexa Therapeutics, Avacta Therapeutics, ProteinQure, Theratechnologies Inc., CBP, Soricimed Biopharma, NMS Group S.p.A., Mainline Scientific LLC., Bicycle Therapeutics, among others Peptide-drug Conjugate Market Assessment Peptide-drug Conjugate Market Segmentation Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View Which MedTech key players in the PDC market are set to emerge as the trendsetter explore @ Peptide-drug Conjugate Companies Table of Contents 1 Peptide-drug Conjugate Market Report Introduction 2 Peptide-drug Conjugate Market Executive Summary 3 Competitive Landscape 4 Regulatory Analysis 5 Peptide-drug Conjugate Market Key Factors Analysis 6 Peptide-drug Conjugate Market Porter's Five Forces Analysis 7 Peptide-drug Conjugate Market Layout 8 Peptide-drug Conjugate Market Company and Product Profiles 9 KOL Views 10 Project Approach 11 About DelveInsight 12 Disclaimer & Contact Us Interested in knowing the PDC market by 2032? Click to get a snapshot of the Peptide-drug Conjugate Market Trends Related Reports Antibody-drug Conjugates in Oncology Competitive Landscape Antibody-drug Conjugates in Oncology Competitive Landscape – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key ADC in oncology companies, including Jiangsu Hengrui Medicine Co., Bio-Thera Solutions, MediLink Therapeutics, Byondis, AbbVie, Oxford BioTherapeutics, Iksuda Therapeutics, Novelty Nobility, LegoChem Biosciences, DualityBio, Lepu Biopharma, Ambrx, CSPC ZhongQi Pharmaceutical Technology, MacroGenics, ADC Therapeutics, Genor Biopharma, CStone Pharmaceuticals, AstraZeneca, Alteogen, Biocity Biopharmaceutics, among others. Antibody-drug Conjugates Competitive Landscape Antibody-drug Conjugates Competitive Landscape – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key ADC companies, including Sorrento Therapeutics, Ambrx, MacroGenics, SOTIO Biotech, Klus Pharma, BioAtla, BiOneCure Therapeutics, Shanghai Miracogen, ProfoundBio, ImmunoGen, Arcus Biosciences, CytomX Therapeutics, RemeGen, Bliss Biopharmaceutical, Aivita Biomedical, CoImmune, Zenith Epigenetics, Sutro Biopharma, Ambrx, Mythic Therapeutics, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical, Byondis, MediLink Therapeutics (Suzhou), Oncomatryx Biopharma, MacroGenics, Shanghai Miracogen, Mirati Therapeutics, Ambrx, Orum Therapeutics, Silverback Therapeutics, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical, Aivita Biomedical, Northwest Biotherapeutics, Daiichi Sankyo, Merck, Pfizer, GSK, AstraZeneca, Eisai, FOSUN PHARMA, LaNova, Mabwell Therapeutics, MBRACE THERAPEUTICS, MINGHUSI PHARMACEUTICALS, BioNTech , Bio-Thera, Corbus Pharmaceuticals, AbbVie, Multitude Therapeutics, Innovent, OnCusp Therapeutics, Simcere, Ymmunobio, Jiangsu Hengrui Medicine, among others. Antibody-drug Conjugates Market Antibody Drug Conjugates Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ADC companies, including Sorrento Therapeutics, Ambrx, MacroGenics, SOTIO Biotech, Klus Pharma, BioAtla, BiOneCure Therapeutics, Shanghai Miracogen, ProfoundBio, ImmunoGen, Arcus Biosciences, CytomX Therapeutics, RemeGen, Bliss Biopharmaceutical, Aivita Biomedical, CoImmune, Zenith Epigenetics, Sutro Biopharma, Ambrx, Mythic Therapeutics, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical, Byondis, MediLink Therapeutics (Suzhou), Oncomatryx Biopharma, MacroGenics, Shanghai Miracogen, Mirati Therapeutics, Ambrx, Orum Therapeutics, Silverback Therapeutics, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical, Aivita Biomedical, Northwest Biotherapeutics, Daiichi Sankyo, Merck, Pfizer, GSK, AstraZeneca, Eisai, FOSUN PHARMA, LaNova, Mabwell Therapeutics, MBRACE THERAPEUTICS, MINGHUSI PHARMACEUTICALS, BioNTech , Bio-Thera, Corbus Pharmaceuticals, AbbVie, Multitude Therapeutics, Innovent, OnCusp Therapeutics, Simcere, Ymmunobio, Jiangsu Hengrui Medicine, among others. Bispecific Antibody Competitive Landscape Bispecific Antibody Competitive Landscape – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key bispecific antibodies companies, including Janssen, Amgen, Akeso, Zymeworks, Roche, IGM Biosciences, MacroGenics, Provention Bio, Jiangsu Alphamab Biopharmaceuticals, Sichuan Baili Pharmaceutical, Regeneron Pharmaceuticals, Boehringer Ingelheim, among others. About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Contact Us Shruti Thakur info@ +14699457679https:// Logo: View original content: SOURCE DelveInsight Business Research, LLP
